Clinical Trial: Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019012) titled 'Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.' on Feb. 26.

Brief Summary: This study is designed to evaluate the change in glycated hemoglobin (HbA1c) levels from baseline to 24 weeks after the combination therapy of cofrogliptin, metformin and SGLT2i (dapagliflozin) in type 2 diabetes mellitus (T2DM) patients with poor control of glucose level by metformin and SGLT2i combination therapy.

Study Start Date: July 30

Study Type: INTERVENTIONAL

Condition: T2DM

Intervention: DRUG: SGLT2i+Metformin+Cofrogliptin

The combination of SGLT2i+Me...